In this edition, we will cover everything from deficit warnings and polling divides to activist demands and pharmaceutical threats. This week’s top stories reveal a government navigating political landmines on spending, healthcare, and public trust.
Carney’s Fiscal Leadership Faces Scrutiny Ahead of Budget 2025
Finance Minister François-Philippe Champagne is set to testify before the House Finance Committee on October 6, following pressure from MPs — led by Bloc Québécois MP Jean-Denis Garon — to clarify the government’s budget timing. The Liberals are expected to table the budget on November 4, but questions remain about whether the traditional spring schedule will resume in 2026.
In an opinion piece for The Hill Times, Kevin Lynch, former clerk of the Privy Council and deputy minister of Finance, and Jim Mitchell, former Privy Council executive, argued that Prime Minister Mark Carney’s government faces its first major test with the November 4 fall budget. They cautioned that with no fiscal update, rising deficits, and ambitious new spending commitments, the budget will be a crucial test of fiscal credibility and the government’s ability to deliver a convincing growth strategy.
Senator Pierre Moreau told Le Devoir that Carney has no plans to reverse Senate reforms, praised Carney’s financial approach as “rigorous,” and reflected on preparing him for francophone debates by playing Bloc leader Yves-François Blanchet.
The Parliamentary Budget Officer (PBO) reinforced these concerns, with its latest Economic and Fiscal Outlook projecting that Canada’s economy will grow by just 1.2% in both 2025 and 2026, with persistent trade tensions expected to lower real GDP by 0.5% by 2030. The report also warned that ongoing deficits will push the federal debt-to-GDP ratio above 43%, raising concerns about the long-term sustainability of fiscal policy.
The outlook noted unemployment rose to 7.1% in August and is expected to stay elevated before gradually declining to 5.6% by 2030. Inflation is projected to ease to 1.6% in 2026 before stabilizing near the Bank of Canada’s 2% target, while the debt service ratio is forecast to climb to 13.7% by 2030.
Interim Parliamentary Budget Officer Jason Jacques warned MPs that Ottawa’s federal finances are on an “unsustainable” path, with the deficit projected at $68.5 billion this year and the debt-to-GDP ratio set to rise for the first time in decades.
Finance Minister François-Philippe Champagne defended the spending as necessary to navigate global trade disruptions, while Prime Minister Mark Carney pledged infrastructure investments and opposition leader Pierre Poilievre accused the Liberals of breaking their promise to “spend less.”
A new Abacus Data poll revealed that Canadians are deeply divided about what Budget 2025 will bring: 35% expect targeted investments with some cuts, while only 14% expect major austerity. Many respondents believe the military, corporations, and the wealthy will benefit the most, while seniors, renters, and first-time homebuyers will be left out. Public sentiment is fragile, with nearly 30% expecting “bad news” and only 15% optimistic about the outcome.
Pharmacare at a Crossroads: Advocates, Critics, and Provinces Clash Over Path Forward
At a Parliament Hill press conference, the Canadian Health Coalition (CHC) — joined by groups like Heart & Stroke — urged that the Liberals deliver on their pharmacare promises with clear timelines and universal, single-payer implementation. CHC called the policy “non-negotiable” and criticized rising military spending as a distraction from health priorities.
Advocacy pressure was reinforced by Frédérique Chabot of Action Canada for Sexual Health and Rights, Jason MacLean of the Canadian Health Coalition, Angela Preocanin of the Canadian Federation of Nurses Unions, and Siobhán Vipond of the Canadian Labour Congress, urged the Liberal government to keep its promise of a universal, single-payer pharmacare program.
At a Parliament Hill press conference, they warned against a “fill-the-gap” approach and launched an ad campaign pressing for action in the upcoming budget. Interim NDP leader Don Davies echoed their concerns, saying that moving toward a mixed model would betray the intent of the Pharmacare Act passed last year.
Meanwhile, the C.D. Howe Institute urged the federal government to shift course to consider a Quebec-style mixed pharmacare model, arguing it would be more fiscally feasible than a universal system projected to cost $39 billion by 2027-28.
Adding to the complexity, a report by the C.D. Howe Institute, which involved contributions from policymakers, health experts, and industry leaders, highlighted the complexities and fiscal challenges posed by a universal pharmacare plan, which would cost approximately $40 billion and is deemed costly, disruptive, and unsustainable. Currently, around 97% of Canadians are covered under some form of drug plan, prompting a suggestion aimed at expanding access for the uninsured or underinsured, using models that have proven effective, such as the mixed public-private systems in place in Quebec.
Business organizations, insurance companies, and industry leaders have echoed these sentiments. The Canadian Association for Pharmacy Distribution Management, the Canadian Life and Health Insurance Association, and Innovative Medicines Canada have all indicated support for the report’s findings, recognizing the need for a pragmatic, fill-in-the-gaps strategy that builds upon the existing infrastructure rather than overhauling it entirely.
U.S. Drug Tariffs and Price Controls Spark New Concerns
U.S. President Donald Trump published on his social media platform that, beginning October 1, the U.S. will impose a 100% tariff on imports and branded or patented pharmaceutical products. Trump also clarified that the tariff will exclude firms that are already constructing pharmaceutical manufacturing facilities in the U.S.
Meanwhile, AstraZeneca has appealed to the U.S. Supreme Court, regarding its dispute over the Medicare drug price negotiation program initiated under the Inflation Reduction Act. The company argued that the program deprives pharmaceutical manufacturers of due process and challenges the constitutionality of allowing the Centers for Medicare & Medicaid Services to set drug prices unilaterally.
AstraZeneca also stated that these mandated price negotiations and cuts will drastically affect the pharmaceutical market, impacting millions of Americans under Medicare.
Healthcare Reform: From Hidden Costs to Innovation Investment
A new Fraser Institute report shed light on the true cost of Canada’s “free” healthcare system. According to their findings, a typical Canadian family of four will pay approximately $19,060 in public health-care costs in 2023, despite the perception of free healthcare services at the point of use. This cost emerges largely from taxation and is a significant figure when considering its distribution through general government revenues, rather than a specified healthcare levy.
The report further breaks down these costs, estimating that a couple without children will pay around $17,338, while single Canadians and single parents with one child will contribute $5,703 and $5,934, respectively.
Supporting this, statistics show that government spending on healthcare accounted for about a third of all provincial and local expenditures in 2023, and national health-related expenses for 2024 are projected to reach $372 billion, representing approximately 12.4% of the GDP. Despite the distribution, the increasing costs raise questions of sustainability and whether Canadians receive good value for their financial contributions to the health-care system.
In contrast, the Life Sciences Ontario (LSO) Forum focused on long-term solutions. At the group’s 16th Annual Ideas to Action Forum, Cate Murray, President and CEO of the Stem Cell Network, urged Canada to adopt a Canada-first strategy to retain talent, modernize clinical trials, and keep regenerative medicine innovations in the country. She cited Canadian advances in restoring sight and treating diabetes, warning that without a coordinated approach, these breakthroughs risked moving abroad. Researcher Timothy Caulfield highlighted the dangers of misinformation in science and called for evidence-based communication to sustain public trust and inform policy.
Meanwhile, according to OBIO, Minister Sylvia Jones outlined the new Health Innovation Pathway, designed to accelerate the adoption of new technologies and reinforce the role of life sciences in economic recovery and health system improvement. Further, LSO reported that industry experts stressed the need for seed capital, greater investment in nuclear medicine and genomics, and stronger industry-academic collaboration to support small and medium-sized enterprises and drive sector growth.
From fiscal credibility to pharmacare promises and U.S. policy shocks, this week further proves just how fragile Canada’s healthcare and economic systems remain. With competing visions for reform and global pressure, the question isn’t whether change is coming, but whose vision will prevail.
Want expert news coverage delivered to your inbox? Book a free consultation today to access our Executive Daily Briefing!
